Analysts/Institutional Investor Meet/Con. Call Updates

Date: 2nd November 2026 The Manager Listing Compliance Department National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051, India Symbol: SAKAR Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Transcript of Con Call. Transcript of the discussion on the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended September 30, 2026, at the analyst meet held on October 27, 2026, is attached and also available on the website of the Company at https://sakarhealthcare.com/wp- content/uploads/2026/11/Sakar-Q2-FY27-Earnings-Conference-Call-Transcript.pdf This is for information and records. Thanking You, Yours faithfully, FOR, SAKAR HEALTHCARE LIMITED BHARAT SONI COMPANY SECRETARY AND COMPLIANCE OFFICER “Sakar Healthcare Limited Q2 and H1 FY27 Earnings Conference Call” October 27, 2026 MANAGEMENT: MR. BIKRAMJIT GHOSH – VICE PRESIDENT, STRATEGY AND BUSINESS DEVELOPMENT – SAKAR HEALTHCARE LIMITED MR. DHARMESH THAKER – CHIEF FINANCIAL OFFICER – SAKAR HEALTHCARE LIMITED MR. BHARAT SONI – COMPANY SECRETARY – SAKAR HEALTHCARE LIMITED MS. PUSHPA PONMANY – MANAGER – SAKAR HEALTHCARE LIMITED MODERATOR: MS. SEJAL – MUFG INTIME Page 1 of 14 Sakar Healthcare Limited October 27, 2026 Moderator: Ladies and gentlemen, good day, and welcome to Sakar Healthcare Limited Q2 H1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Sejal from MUFG. Thank you, and over to you, Ms. Sejal. Sejal: Thank you, Siddhant. Welcome to Sakar Healthcare Q2 and H1 FY27 earnings con-call. Today on the call, we have Mr. Bikramjit Ghosh, Vice President, Strategy and Business Development; Mr. Dharmesh Thaker, CFO; Mr. Bharat Soni, Company Secretary; and Ms. Pushpa Ponmany, Manager. Before we proceed with the call, I would like to give a small disclaimer that the call may contain certain forward-looking statements which are based on the business opinions and expectations of the company as on date. A detailed disclaimer has been given in the company's investor presentation, which is uploaded on the stock exchange. Now I would like to hand over the call to Ms. Pushpa. Over to you, ma'am. Pushpa Ponmany: Thank you. Good afternoon, everyone, and thank you for joining Sakar Healthcare's Q2 and H1 FY27 earnings conference call. On behalf of the management team, I extend a warm welcome to our shareholders, investors, analysts, and business partners. We appreciate your continued trust and support. The first half of FY27 has been marked by strong execution across our oncology platform. Beyond the encouraging financial performance, we have made meaningful progress in regulatory approvals, customer engagements, technology transfers, and commercialization activities, strengthening the foundation for sustainable long-term growth. During the period, we executed 69 oncology product contracts and are actively engaged in discussions for an additional 45 opportunities across international markets. These engagements reinforce confidence in our development, regulatory, and manufacturing capabilities, while providing visibility for future growth. Our regulatory pipeline continues to advance steadily. We have now shared 351 oncology dossiers globally, with 191 submissions made to regulatory agencies and 22 marketing authorizations granted. These approvals include 11 in Europe and the UK, 6 in Latin America, 4 in Myanmar, and 1 in Canada. We also completed 36 European marketing authorization filings, including 16 proprietary filings. In parallel, we submitted 33 site variations covering 18 cytotoxic molecules, with approvals already received for 11 products across the European Union and the United Kingdom. Further strengthening our global presence, Accord received six additional EMA site variation approvals at our oncology facility, taking the total approvals to 8 out of 11 molecules. Page 2 of 14 Sakar Healthcare Limited October 27, 2026 We also secured three additional approvals from the MHRA and EMA through our partners in the UK and Germany, supporting future commercial supplies. Our CDMO business continues to gain momentum, with 33 technology transfer projects currently underway across our four partners. On the backward integration front, we have developed 21 oncology APIs in-house, including 16 APIs with written confirmation. Eight products have already been commercialized, while two of our seven CEP applications have been approved and the remaining applications continue to progress through the regulatory review process. We are now seeing the benefits of our integrated oncology strategy. Commercial supplies have commenced in both domestic and international markets from our API integrated EU GMP-approved oncology formulations facility, reflecting our ability to combine development, regulatory, API, formulation capabilities into a scalable commercial model. Our oncology portfolio has also expanded considerably and today addresses a broad range of therapies covering cancers of breast, lungs, prostate, stomach, head and neck, colorectal, ovarian, liver, kidney, thyroid, as well as blood, bone marrow, and lymphatic cancers. This diversification broadens our addressable opportunity while reducing concentration on any single therapy area. Turning to our financial performance, revenue operations for Q2 FY27 grew 52% year-on-year to INR8,741.61 lakhs, while H1 FY27 revenue increased 45% to INR16,038.86 lakhs. Q2 EBITDA more than doubled, rising 114% to INR2,434.53 lakhs, with EBITDA margin improving to 28% from 20%. H1 EBITDA increased 90% to INR4,559.42 lakhs, with margins expanding to 28% from 22%. Profit after tax grew 149% to INR1,130.69 lakhs in Q2 FY27 and 134% to INR2,159.18 lakhs in H1 FY27. The improvement in profitability reflects a stronger business mix, operating leverage, and the increasing contribution of our oncology business. Looking ahead, our focus remains on converting approvals into commercial opportunities, expanding customer partnerships, advancing technology transfers, and strengthening our position in global oncology markets. The progress achieved across approvals, customer engagement, CDMO projects, and commercial supplies provides confidence in our long-term growth strategy. Before I conclude, I would like to thank our Chairman and Managing Director, Mr. Sanjay Shah, the Board of Directors, employees, customers, partners, and shareholders for their continued support and trust. With that, I request the moderator to open the floor for questions. Thank you. Moderator: Thank you. We will now begin the question-and-answer session. The first question is from the line of Priyanshu Jain from Growth X Infinity. Please go ahead. Priyanshu Jain: Hi. Am I audible? Bikramjit Ghosh: Yes. Page 3 of 14 Sakar Healthcare Limited October 27, 2026 Priyanshu Jain: Hi, sir. Congratulations, first of all, on a great set of execution. I have a few questions. First will be on the revenue mix side. So, for upcoming 2 to 3 years, can you give me the percentage of the revenue mix which we are targeting from our each business segment? Bikramjit Ghosh: Yeah. This is Bikramjit this side. Currently, if you see the revenue mix in terms of both the oncology and non-oncology are moving in head-to-head, considering that non-oncology was predominant till the last financial year. But going ahead, the oncology contribution will grow in a substantial percentages based on the infrastructure what we are having presently for that particular setup. And we expect that it will be contributing the maj [Showing first 8,000 characters — download PDF for full document]